« back to reports
Medtech Public Comp Sheet and Valuation Guide

Q1 2024

Medtech Public Comp Sheet and Valuation Guide

April 9, 2024

Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
 

Innovation is name of the game in public medtech

Surgical robotics startups, led by Softbank-backed CMR Surgical, are our picks for the medtech IPO vanguard when the window opens. The subsector has held strong within the industry, and the stocks of similar less-profitable yet higher-growth companies have drawn investor interest.

In general, public medtech valuations have steadied after a drawn-out decline, and EBITDA multiples are on the rise in the medical devices, consumer health, and life sciences segments.

Our Q1 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performance, EBITDA margins, revenue growth, and valuations for key publicly traded companies.


Table of contents
Key takeaways 2
Stock returns 4
Valuations 5
Revenue 6
EBITDA 7